Why the next generation of model-informed development will depend on context, credibility, connected evidence and accountable workflows
Before artificial intelligence became the dominant language of drug development, the industry was already asking a more fundamental question:
How can models help us improve processes and make better decisions under uncertainty?
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Translate Life Science and Technology Innovation into Adoption and
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Translate Life Science and Technology Innovation into Adoption and
Nilou Sarah Arden, PhD Strategic Advisor | Ex-FDA | Helping Leaders Translate Life Science and Technology Innovation into Adoption and
Vaccines, oncology, and rare disease programs each carry distinct cost structures, attrition profiles, and funding dynamics. Understanding the differences serves
Drug development is expensive, slow, and brutally competitive. A Phase 3 study failure costs hundreds of millions of dollars. A
When developing novel life science technologies, drugs, biologics, and gene or cell therapies, how often do early-stage teams conduct a
*A summary of Pathway Capital’s whitepaper on regulatory strategy in early-stage life science investment There is a gap in how
